Tirzepatide
Methamphetamine Use Disorder
University of Texas Southwestern Medical Centerprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Methamphetamine Use Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Seroquel® University of Texas Southwestern Medical Center | N/A | D |
Risperdal University of Texas Southwestern Medical Center | N/A | D |
Same molecule, other indications
Tirzepatide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →